Kayla Judd, APRN
Primary Care · Jamestown, TNNPI 1346905072
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations.
Across 130 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$381
- AbbVie$256
- Lilly USA, LLC$252
- AstraZeneca$228
- Lundbeck LLC$182
- Amgen$139
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,487100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 29 | $381 |
| AbbVie | 10 | $256 |
| Lilly USA, LLC | 15 | $252 |
| AstraZeneca | 9 | $228 |
| Lundbeck LLC | 10 | $182 |
| Amgen | 9 | $139 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $114 |
| SPR Therapeutics, Inc | 3 | $108 |
| Medtronic | 1 | $106 |
| Hikma Pharmaceuticals USA | 4 | $74 |
| Tersera Therapeutics LLC | 4 | $72 |
| Collegium Pharmaceutical, Inc. | 5 | $71 |
| Boston Scientific | 1 | $56 |
| Painteq LLC | 3 | $56 |
| Scilex Pharmaceuticals Inc. | 3 | $52 |
| Saluda Medical Americas, Inc. | 2 | $47 |
| Nevro Corp. | 2 | $38 |
| GRT US Holding, Inc. | 2 | $37 |
| Novo Nordisk | 2 | $36 |
| Exact Sciences | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Pfizer | 2 | $28 |
| Johnson & Johnson | 1 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Nalu Medical, Inc. | 1 | $20 |
| Vertos Medical, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HawkOne$106
How this compares
$2,487 in reported general payments places this provider in the 80th percentile of 189 primary care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 143 | $159,468 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 196 | $145,663 |
| OzempicSemaglutide | 95 | $115,694 |
| JardianceEmpagliflozin | 110 | $85,128 |
| EliquisApixaban | 91 | $68,892 |
| FarxigaDapagliflozin Propanediol | 77 | $59,171 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $52,550 |
| VraylarCariprazine Hcl | 31 | $52,406 |
| RybelsusSemaglutide | 32 | $38,079 |
| XareltoRivaroxaban | 38 | $27,044 |
| Repatha SureclickEvolocumab | 42 | $27,025 |
| UbrelvyUbrogepant | 16 | $25,435 |
| Diclofenac Potassium | 15 | $24,337 |
| TrulicityDulaglutide | 23 | $21,997 |
| KerendiaFinerenone | 18 | $21,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Farxiga | $228 | $204,835273 claims |
| Lilly USA, LLCMounjaro, Trulicity | $252 | $181,466166 claims |
| Novo NordiskOzempic, Rybelsus | $36 | $153,773127 claims |
| AbbVieVraylar, Ubrelvy, Qulipta, Linzess | $256 | $105,27679 claims |
| PfizerEliquis | $28 | $68,89291 claims |
| Johnson & JohnsonXarelto | $27 | $27,04438 claims |
| BayerKerendia | $381 | $21,47118 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $52 | $12,40415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 189 primary care providers in Tennessee.
Other primary care in Jamestown
- Mary SullivanGermantown$115K
- Len GetzMemphis$25K
- Judith CaldwellNashville$18K
- Mara HutchingsNashville$14K
- Reena BhaktaMurfreesboro$12K
- Ryan HartmanNashville$11K
- Martha LemonsBrentwood$11K
- Abigail EubankHendersonville$9K
- Corey ClelandSevierville$9K
- Katie JohnsonClarksville$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.